Verified peer comparison

JNJ vs NVO

Johnson & Johnson compared with Novo Nordisk A/S. This page compares both source-verified company profiles and does not introduce an unverified price target.

JNJ

Johnson & Johnson

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

NVO

Novo Nordisk A/S

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

JNJ: Pharmaceuticals

NVO: Pharmaceuticals

Upside lens

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

NVO: Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. Fill-finish and active-ingredient investments can improve supply and support broader launches. Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.

Risk lens

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

NVO: Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity. Payer restrictions, government negotiation and affordability concerns can reduce realized economics. Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.